Table 1.

Reproducibility of the detection of KRASG12/G13 mutations in urine cfDNA from patients with advanced cancer

Patient, replicateKRAS variantKRASG12/G13 copiesCV%Average CV%
1, 118.29
1, 2G12S17.812.3
1, 318.66
2, 1G13D195.027.09.7
2, 2176.57
3, 110.43
3, 2G12D7.2619.6
3, 37.91
  • NOTE: Two to three urine cups (each 90–120 mL) were collected at a single time point from 3 patients with known KRAS mutational status in tumor biopsies. Following urine extraction, cfDNA was assayed by mutation-enrichment NGS. Intra- and interpatient reproducibility was calculated as CV%.